Precision-gated recovery hypothesis

PDF page 9 Cancer requires special caution. Psychosocial state is not a broad cancer cure. It can only be hypothesised as a gain modifier when tumour biology, immune accessibility, treatment opportunity, and threshold proximity align. Cancer immunoediting already provides a host-control grammar of elimination, equilibrium, and escape [12,13]. Psychoneuroimmunology and social genomics provide measurable channels by which chronic threat, isolation, and support can relate to inflammatory and antiviral gene-expression patterns [14,15], while psycho-oncology meta- analytic evidence suggests immune effects of psychological intervention are heterogeneous and not reliable survival cures [16]. Empirical data No new empirical datasets are reported in this hypothesis article. The hypothesis is evaluated against already published findings on placebo effects, spontaneous cancer regression, active inference, psychoneuroimmunology, cancer immunoediting, and early-warning signals for critical transitions. The proposed atlas, simulation tests, and prospective dense-sampling studies are offered as future empirical tests rather than as completed validation. Hypothesis testing The primary empirical signature is not generic critical slowing down. Rising autocorrelation and variance occur near many folds [17-19]; they are useful but not specific. The discriminating prediction is rising fast-slow coupling before transition (Fig. 3). Mechanistically, capture increases the gain by which fast evidence updates slow host state: precision reallocation raises the effective γ(t) linking y_fast to y_slow. A fixed-coupling null may have two levels, but its γ(t) should not increase because capture has not changed the gain. A minimal state-space test is y_slow(t+1) = α_t y_slow(t) + γ_t y_fast(t-lag) + η_t. The theory predicts increasing γ_t before precision-gated transitions only after matched comparison with fixed-coupling, delayed-feedback, common-driver, and treatment-only threshold/accumulation nulls. Recent dense-sampling work on affective transitions shows why such time-resolved designs are plausible and why early-warning signals are expected to be patchy rather than universal [18,20]. The strongest retrospective test is an Exceptional Recovery Atlas. Cases should be tiered by diagnostic strength and treatment adequacy, then matched to non-recovery controls by diagnosis, stage or severity, age, baseline prognosis, treatment exposure, and follow-up. Narrative variables must be coded from outcome-redacted material, because certainty and meaning occur in non-recoveries too. For very rare cancer regressions, dense fast-slow time series may be infeasible; the appropriate test is trigger enrichment, treatment adequacy review, diagnostic strength, and documented temporal ordering. For common or recurrent transitions such as pain, IBS, depression relapse/remission, fatigue, breathlessness, or psychogenic symptom reversal, prospective dense sampling can test capture-policy-host timing directly. Prospective testing should pre-specify capture independently of outcome. One candidate criterion is a ≥2 standard- deviation increase from an individual's baseline certainty/expectancy rating, sustained across at least three consecutive ecological momentary assessments, before the outcome change being predicted. Dense sampling could combine ecological momentary assessment with wearable heart-rate variability or resting heart-rate measures, sleep/activity sensing, respiration, treatment-adherence logs, symptom scores, and disease-appropriate biomarkers. Neural spectral monitoring may be exploratory where available, but the core test is temporal ordering rather than any single device. The social prediction is especially sharp. A trusted clinician, parent, partner, healer, or community should not help everyone equally. Social certainty should have little additional effect in patients already above threshold and little effect far below threshold, but large effect near the capture threshold. A uniform main effect of support would favour ordinary psychosocial models over the threshold-local version proposed here. Before empirical claims are made, simulation robustness is required. The rising-coupling signature should be tested across timescale separation, noise, coupling strength, capture threshold, disease pressure, trigger duration, missing data, and coordinate choice. It should be compared against fixed-coupling, common-driver, delayed-feedback, treatment-only, drift, and autoregressive symptom-fluctuation nulls. The artanh coordinate is only a candidate; raw, logit, and probit alternatives should be compared because coordinate choice can create or hide apparent bistability. Consequences of the hypothesis and discussion If correct, the hypothesis reframes exceptional recovery as anomaly cartography rather than miracle proof or embarrassing noise. It predicts that rare recovery depends on coupled thresholds rather than generic positivity. It also PDF page 10 predicts many failures: no biological gate, no durable capture, no policy transduction, excessive disease pressure, or absence of trigger opportunity. The clinical implication is conservative. Do not replace evidence-based care and do not pressure patients to believe. Instead, treat care as occurring inside a human inference-and-control system. The specific prediction is threshold- local: identify genuine early proof when it occurs, protect the conditions that let it become policy and physiological stability, and avoid adding threat where no biological gate is accessible. Reduce unnecessary threat; protect sleep, appetite, movement, and connection; strengthen agency where real agency exists; allow meaning and spiritual practice when desired; and measure early proof carefully. Failure to recover never implies insufficient belief, faith, love, or will. It may mean that the biological gate was inaccessible, the trigger absent, treatment unavailable, disease pressure too high, or policy space constrained by pain, poverty, trauma, isolation, or physiology. The same architecture can run negatively. A transient worsening may be captured as proof of terminal decline; precision shifts toward a death prior; policy contracts; autonomic stress rises; and deterioration accelerates. This nocebo or terminal-identity ratchet predicts that threat capture should precede policy contraction and worsening host markers, providing an independent negative-direction test. The hypothesis can fail. It fails if recovery and matched non-recovery cases cannot be separated by evidence- capture-policy-host timing. It fails if trusted-source certainty acts as a uniform main effect rather than threshold-local crossover. It fails in cancer if regression cases are not enriched for plausible biological triggers, treatment opportunities, or accessible host-control gates compared with matched non-regression controls. A model that explains every recovery and every non-recovery after the fact would explain nothing. The principal limitation is that the present paper is a hypothesis, not a validation study. The formal model organises known observations and generates tests; it does not prove that real organisms use this architecture. The next step is not stronger rhetoric but blinded coding, negative controls, null-model simulation, and prospective dense sampling.

Precision-gated attractor reversal: a triple-threshold hypothesis for exceptional recovery Research Article—Hypotheses Running title: Precision-gated attractor reversal Abstract Exceptional recovery—including sudden symptom resolution, placebo response, spontaneous remission, radical remission, and exceptional treatment response—is usually dismissed as anecdote or romanticised as evidence that belief overcomes disease. Both views are incomplete. Drawing on active inference and precision weighting, I propose a triple-threshold hypothesis: recovery requires an evidence event, capture of that event as credible survival evidence, and access to a host-control gate, meaning a disease-relevant immune, endocrine, autonomic, tissue, reflex, or treatment-response system able to alter trajectory. Captured evidence may reallocate precision from an illness prior to survival evidence, alter policy/autonomic regulation, and only then affect biology. This explains why shallow loops can reverse abruptly, why predictive-body syndromes may require repeated proof and safety learning, and why structural diseases rarely reverse without treatment opportunity, immune/inflammatory trigger, or threshold proximity. The model predicts weak psychosocial main effects in deep disease but stronger threshold-local interactions, rising fast-slow coupling before transition, and trigger enrichment in cancer regression cases. Keywords: exceptional recovery; placebo; spontaneous remission; active inference; precision; attractor Introduction/background Medicine explains ordinary outcomes well, but it remains uncomfortable with rare recoveries that appear too large, change, and tumour-microenvironment shift as recurring correlates [6,7]. Because this literature is dominated by case reports and reviews of variable quality, it demands diagnostic tiering rather than credulous acceptance. Radical- remission and prayer-associated recovery narratives are also not proof, but they may be hypothesis-generating records of agency, certainty, meaning, social holding, and biological trigger alignment [8,9]. Hypothesis The hypothesis is that some exceptional recoveries are precision-gated attractor reversals: multiscale transitions in which an illness-stabilising basin loses precision, survival evidence gains precision, policy changes, and a host- control threshold may be crossed. The novelty is not placebo response, psychosocial modulation, active inference, or critical transitions taken separately; it is the proposed ordering constraint that exceptional recovery requires their threshold-local conjunction.

new evidence, creating a proof ratchet rather than a one-off placebo input. Glossary and operational definitions Capture threshold: level at which a fluctuation is treated as meaningful evidence rather than noise. Prospectively, capture must be pre-specified and measured before outcome is known. It should be indexed primarily by cognitive-affective variables such as abrupt change in self-rated certainty/expectancy, loss of doubt, or durable reinterpretation, not by later clinical outcome. Meta-precision: confidence assigned to whether an event should count as evidence at all. state v_t is represented locally by x. Fast variables such as m(t) and q(t) influence the control tilt c(t) only through precision allocation, policy, trigger strength, and disease pressure. The equation is a normal-form scaffold for hypothesis testing, not a fitted biological law. Access depth and cancer boundary conditions Access depth determines plausibility. Hiccups and panic surges are shallow reflex loops; a single high-precision update may interrupt them. Pain, irritable bowel symptoms, fatigue, insomnia, and breathlessness are deeper predictive-body loops; they may require repeated proof and safety learning. Structural disease is deeper again and requires biological gate access. The framework does not claim that belief cures disease; it specifies where such a claim should fail.

Cancer requires special caution. Psychosocial state is not a broad cancer cure. It can only be hypothesised as a gain modifier when tumour biology, immune accessibility, treatment opportunity, and threshold proximity align. Cancer immunoediting already provides a host-control grammar of elimination, equilibrium, and escape [12,13]. Psychoneuroimmunology and social genomics provide measurable channels by which chronic threat, isolation, and support can relate to inflammatory and antiviral gene-expression patterns [14,15], while psycho-oncology meta- cures [16]. Empirical data No new empirical datasets are reported in this hypothesis article. The hypothesis is evaluated against already published findings on placebo effects, spontaneous cancer regression, active inference, psychoneuroimmunology, cancer immunoediting, and early-warning signals for critical transitions. The proposed atlas, simulation tests, and prospective dense-sampling studies are offered as future empirical tests rather than as completed validation. Hypothesis testing The primary empirical signature is not generic critical slowing down. Rising autocorrelation and variance occur near many folds [17-19]; they are useful but not specific. The discriminating prediction is rising fast-slow coupling before transition (Fig. 3). Mechanistically, capture increases the gain by which fast evidence updates slow host state: precision reallocation raises the effective γ(t) linking y_fast to y_slow. A fixed-coupling null may have two levels, but its γ(t) should not increase because capture has not changed the gain. A minimal state-space test is y_slow(t+1) = α_t y_slow(t) + γ_t y_fast(t-lag) + η_t. The theory predicts increasing γ_t before precision-gated transitions only after matched comparison with fixed-coupling, delayed-feedback, common-driver, and treatment-only threshold/accumulation nulls. Recent dense-sampling work on affective transitions shows why such time-resolved designs are plausible and why early-warning signals are expected to be patchy rather than universal [18,20]. The strongest retrospective test is an Exceptional Recovery Atlas. Cases should be tiered by diagnostic strength and be infeasible; the appropriate test is trigger enrichment, treatment adequacy review, diagnostic strength, and documented temporal ordering. For common or recurrent transitions such as pain, IBS, depression relapse/remission, fatigue, breathlessness, or psychogenic symptom reversal, prospective dense sampling can test capture-policy-host timing directly. Prospective testing should pre-specify capture independently of outcome. One candidate criterion is a ≥2 standard- deviation increase from an individual's baseline certainty/expectancy rating, sustained across at least three consecutive ecological momentary assessments, before the outcome change being predicted. Dense sampling could combine ecological momentary assessment with wearable heart-rate variability or resting heart-rate measures, sleep/activity sensing, respiration, treatment-adherence logs, symptom scores, and disease-appropriate biomarkers. Neural spectral monitoring may be exploratory where available, but the core test is temporal ordering rather than any single device. The social prediction is especially sharp. A trusted clinician, parent, partner, healer, or community should not help everyone equally. Social certainty should have little additional effect in patients already above threshold and little effect far below threshold, but large effect near the capture threshold. A uniform main effect of support would favour ordinary psychosocial models over the threshold-local version proposed here. Before empirical claims are made, simulation robustness is required. The rising-coupling signature should be tested treatment-only, drift, and autoregressive symptom-fluctuation nulls. The artanh coordinate is only a candidate; raw, logit, and probit alternatives should be compared because coordinate choice can create or hide apparent bistability. Consequences of the hypothesis and discussion If correct, the hypothesis reframes exceptional recovery as anomaly cartography rather than miracle proof or embarrassing noise. It predicts that rare recovery depends on coupled thresholds rather than generic positivity. It also

predicts many failures: no biological gate, no durable capture, no policy transduction, excessive disease pressure, or absence of trigger opportunity. The clinical implication is conservative. Do not replace evidence-based care and do not pressure patients to believe. Instead, treat care as occurring inside a human inference-and-control system. The specific prediction is threshold- local: identify genuine early proof when it occurs, protect the conditions that let it become policy and physiological stability, and avoid adding threat where no biological gate is accessible. Reduce unnecessary threat; protect sleep, appetite, movement, and connection; strengthen agency where real agency exists; allow meaning and spiritual practice when desired; and measure early proof carefully. Failure to recover never implies insufficient belief, faith, The same architecture can run negatively. A transient worsening may be captured as proof of terminal decline; precision shifts toward a death prior; policy contracts; autonomic stress rises; and deterioration accelerates. This nocebo or terminal-identity ratchet predicts that threat capture should precede policy contraction and worsening host markers, providing an independent negative-direction test. The hypothesis can fail. It fails if recovery and matched non-recovery cases cannot be separated by evidence- capture-policy-host timing. It fails if trusted-source certainty acts as a uniform main effect rather than threshold-local crossover. It fails in cancer if regression cases are not enriched for plausible biological triggers, treatment opportunities, or accessible host-control gates compared with matched non-regression controls. A model that explains every recovery and every non-recovery after the fact would explain nothing. The principal limitation is that the present paper is a hypothesis, not a validation study. The formal model organises known observations and generates tests; it does not prove that real organisms use this architecture. The next step is not stronger rhetoric but blinded coding, negative controls, null-model simulation, and prospective dense sampling.